[Evaluation of concomitant use of non-specific immunopotentiator on 172 cases of primary lung cancer (stage III, IV) treated with radiation combined with chemotherapy (author's transl)].
D000236:Adenoma / Q000628:therapy; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D011509:Proteoglycans / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D001688:Biological Products; D011509:Proteoglycans; D010844:Picibanil; C010770:polysaccharide-K